Related Experiment Videos
Marked rebound acid hypersecretion after treatment with ranitidine
E el-Omar1, S Banerjee, A Wirz
1University Department of Medicine and Therapeutics, Western Infirmary, Glascow, United Kingdom.
This study investigated how stopping ranitidine, a drug used to reduce stomach acid, affects acid production in healthy people. Researchers found that after discontinuing ranitidine, acid output increased significantly in both people with and without Helicobacter pylori infection. The increase was measured both at rest and when stimulated by gastrin-releasing peptide. However, this rebound effect did not correlate with changes in gastrin levels. The authors suggest that this rebound acid secretion may explain why symptoms like heartburn return quickly after stopping ranitidine. The study highlights the importance of understanding how acid suppression drugs affect gastric function when they are discontinued.
Area of Science:
- Gastroenterology and digestive system disorders
- Pharmacology of acid suppression therapies
- Clinical trials in healthy human volunteers
Background:
Dyspeptic symptoms often return quickly after stopping acid-suppressing drugs like ranitidine. This pattern may relate to increased acid production following treatment. Prior research has shown that H2 antagonists reduce gastric acid secretion. However, no prior work had resolved whether this effect leads to a rebound increase in acid output after drug withdrawal. Established knowledge includes the role of gastrin in regulating acid secretion. The mechanism of rebound acid hypersecretion remains unclear. No prior work had resolved how Helicobacter pylori infection might influence this rebound effect. This gap motivated a study in healthy volunteers to measure acid output changes after ranitidine discontinuation. The uncertainty about the duration and magnitude of this rebound effect led to the current investigation.
Purpose Of The Study:
The aim of this study was to evaluate acid secretion changes after ranitidine withdrawal in healthy individuals. Researchers focused on whether stopping ranitidine leads to a rebound increase in acid output. They also examined if Helicobacter pylori infection affects this rebound. The study aimed to measure both basal and gastrin-releasing peptide-stimulated acid output. They sought to determine if these changes correlate with gastrin levels. The motivation came from clinical observations of rapid symptom recurrence after H2 antagonist withdrawal. No prior work had resolved the timeline of acid rebound after ranitidine discontinuation. This study aimed to clarify the relationship between drug withdrawal and acid secretion dynamics.
Main Methods:
The study involved 18 healthy volunteers, nine of whom were Helicobacter pylori positive. Participants received ranitidine 300 mg nightly for 60 days. Acid output was measured before treatment and at 60 hours and 10 days post-treatment. Basal and gastrin-releasing peptide (GRP)-stimulated acid output were assessed. Gastrin concentration was also measured at each time point. The study design included a baseline measurement before drug administration. Researchers compared pretreatment values with those after ranitidine discontinuation. The use of GRP allowed for stimulation of acid secretion beyond basal levels. This approach enabled the assessment of both spontaneous and stimulated acid output changes.
Main Results:
Basal acid output increased by 137% in H. pylori-negative volunteers two days after ranitidine discontinuation. GRP-stimulated acid output rose by 108% in the same group. These values returned to baseline by day 10. In H. pylori-positive volunteers, basal acid output increased by 96% two days post-treatment. GRP-stimulated output increased by 56% in this group. Both values returned to baseline by day 10. Gastrin concentrations did not rise in either group during the study period. These findings suggest a direct effect of ranitidine withdrawal on acid secretion. The increase in acid output was not accompanied by changes in gastrin levels.
Conclusions:
Ranitidine therapy is associated with a significant rebound increase in acid secretion after discontinuation. This rebound effect occurs in both H. pylori-positive and -negative individuals. The increase in acid output is observed both at baseline and in response to GRP stimulation. The authors propose that this rebound may explain the rapid return of dyspeptic symptoms after stopping ranitidine. The study found no correlation between acid rebound and changes in gastrin levels. These findings suggest a direct effect of ranitidine withdrawal on gastric acid production. The authors state that this rebound effect could contribute to the clinical recurrence of symptoms. Their findings support the hypothesis that H2 antagonists may lead to a temporary overproduction of gastric acid.
Frequently Asked Questions
The study found a significant rebound increase in acid output after ranitidine discontinuation, with basal acid output rising by 137% in H. pylori-negative volunteers.
Acid output was measured using basal and gastrin-releasing peptide (GRP)-stimulated tests before and after ranitidine discontinuation.
The study compared acid rebound in H. pylori-positive and -negative individuals to determine if infection status influences the effect of ranitidine withdrawal.
No, gastrin concentrations did not rise in either H. pylori-positive or -negative subjects during the study period.
The rebound acid output returned to pretreatment levels by day 10 after ranitidine discontinuation in both groups.
The authors propose that the rebound acid hypersecretion may explain the rapid resurgence of dyspeptic symptoms after stopping ranitidine therapy.